Epalrestat CAS 82159-09-9 Puritas >99.5% (HPLC) Factory
Shanghai Ruifu Chemical Co., Ltd. est primarium fabricae Epalrestatae (CAS: 82159-09-9) cum qualitate alta.Ruifu Chemical traditio terrarum, quantitatis competitive, parvae et quantitatis quantitatis in promptu est, praebere potest.Emptio Epalrestat;Please contact: alvin@ruifuchem.com
| Nomen chemicum | Epalrestat |
| Synonyma | Epalrest;ONO-2235;Eabeth;Kinedak;Sorbistat;(5Z)-5-[(2E)-2-Methyl-3-phenyl-2-propen-1-ylidene]-4-oxo-2-thioxo-3-Thiazolidineacetic Acidum;2-[(5Z)-5-[(E)-3-Phenyl-2-methylprop-2-enylidene]- 4-oxo-2-thioxo-3-thiazolidinyl] Acidum aceticum;(E, E) -2-[5-(2-Methyl-3-phenyl-prop-2-enylidene) -4-oxo-2-sulfanylidene-thiazolidin-3-yl] acidum aceticum |
| Stock Status | In Stock, Massa Productio |
| CAS Number | 82159-09-9 |
| Formulae hypotheticae | C15H13NO3S2 |
| M. Pondus | 319.39 g/mol |
| Liquescens punctum | 222.0 ad 226.0℃ |
| Density | 1.43±0.10 g/cm3 |
| Solubilitas | DMSO 2 mg/mL Aquae <1 mg/mL Ethanol<1 mg/mL |
| Repono Nativ. | Frigus & siccum (-20℃) |
| COA & MSDS | Praesto |
| Categoria | API |
| Brand | Ruifu Chemical |
| Items | Signa inspectionis | Proventus |
| Aspectus | Orange to Orange Red Crystalline Pulvis | Obsequitur |
| Lepidium sativum | Idem est in HPLC retentione tempore vexillum | Transi |
| Liquescens punctum | 222.0 ad 226.0℃ | 222.4~224.3℃ |
| Damnum in Siccatio | <0.50% | 0.04% |
| Residere in Ignition | <0.20% | 0.04% |
| Metalla gravia (Pb) | ≤20ppm | <20ppm |
| Totalis immunditias | ≤0.50% | 0.20% |
| Puritas / Analysis Methodus | >99.5% (HPLC) | 99.8% |
| Infrared Imaginis | Conformat ut Structure | Obsequitur |
| conclusio | Productum probatum est & obsequitur datis specificationibus | |
Sarcina:Utrem, aluminium foil, sacculum, 25kg/cardboard Drum, vel secundum exigentiam emptoris.
Repono Condition:Condite in vasis obsignatis apud frigus et siccum (-20℃) horreum ab substantiis incompossibilibus.A luce et humore protege.
Naviportans:Libera ad orbem terrarum per FedEx / DHL Express.Ieiunium et certas traditiones provide.
Quam mercari?Quaeso contactumDr. Alvin Huang: sales@ruifuchem.com or alvin@ruifuchem.com
15 Years Experience?Plus quam XV annos experientiae habemus in fabricando et exportando amplis intermediis pharmaceuticis vel alchimicis pharmaceuticis amplis.
Mercatus principalis?Vendere mercatum domesticum, Americam septentrionalem, Europam, Indiam, Coream, Iaponicam, Australiam etc.
Commodi?Superior qualitas, parabilis pretium, officia professionalia et subsidia technica, ieiunium partus.
Qualitasfides?Qualitas strictioris temperantiae ratio.Pro instrumento analysi professionali includuntur NMR, LC-MS, GC, HPLC, ICP-MS, UV, IR, OR, KF, ROI, LOD, MP, Claritas, Solubilitas, Microbialis limes test, etc.
Exempla?Pleraque producta praebent exempla gratuita pro qualitate aestimationis, sumptus naviculas a clientibus solvendos.
Factory Audit?Factory audit gratissimum.Quaeso ante constitutum.
MOQ?Nec MOQ.Parvus ordo placet.
Tempus adferendi? Si intus prosapia, tres dies partus praestatur.
Transportatio?Per Express (FedEx, DHL), ab Air, per Mare.
Documenta?Post servitium venditionis: COA, MOA, ROS, MSDS, etc. praeberi possunt.
Consuetudo Synthesis?Consuetudo synthesis officia praebere potest ad optimas investigationes tuas necessitates aptandas.
Pensio conditio?Proforma cautionis primum post confirmationem ordinis mittetur, informationes nostrae ripae inclusas.Payment by T/T (Telex Transfer), PayPal, Western Union, etc.
UN IDs 2811
WGK Germania 3
RTECS XJ5131855
Aleam Class 6.1
Stipare Group II
Epalrestat (CAS: 82159-09-9) est secundus aldose reductase inhibitor terrarum introducendae et primus in Iaponia deducendus.Epalrestat indicatur neuropathiae diabeticae curationi.Quaeritur etiam de retinopathy diabetica et nephropathia.Epalrestat est aldose reductase inhibitor cum IC50 72 nM.
Epalrestat vetat Aldose Reductase (AR) implicatum in rate limitantem gradum conversionis glucosi ad sorbitolum sub conditionibus hyperglycemicis.Aldose reductase scopum multiplex investigatorum clinicorum fuit ad diabeticam neuropathiam et retinopathy tractandam.Epalrestat medicamentum probatum in Iaponia et India, adhibitum ad tractationem diabeticae neuropathiae.
Epalrestat praecavens, ameliorata et neuropathia peripherica (torpor, dolor), paresthesiae vibrationales, et deprauatio cardiaca cum diabete coniunguntur.
Epalrestat ut suum pharmacum repraesentativum cumulum fructosi et sorbitoli intracellularem reducit per conversionem inhibendo aldose reductasim activitatem, restaurat Na+-K+-ATPase et inositolam, NO formationem in cellulis endothelialibus auget, interdum kinasum C semitam significat, cellam endothelialem adhaesionem, altam glucose-. mediata neutrophila et adhaesio endothelialis factoris expressionis et carboxymethyl lysinum productos in aegros diabeticos reducit, ita morbos ut diabetes eiusque inpedimenta curans.
